CN103596956A - 吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途 - Google Patents

吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途 Download PDF

Info

Publication number
CN103596956A
CN103596956A CN201280027766.8A CN201280027766A CN103596956A CN 103596956 A CN103596956 A CN 103596956A CN 201280027766 A CN201280027766 A CN 201280027766A CN 103596956 A CN103596956 A CN 103596956A
Authority
CN
China
Prior art keywords
alkyl
compound
methyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280027766.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·赫拉尔
T·A·查比
J·M·汉姆弗利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN103596956A publication Critical patent/CN103596956A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280027766.8A 2011-06-07 2012-05-24 吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途 Pending CN103596956A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494070P 2011-06-07 2011-06-07
US61/494,070 2011-06-07
PCT/IB2012/052627 WO2012168817A1 (en) 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Publications (1)

Publication Number Publication Date
CN103596956A true CN103596956A (zh) 2014-02-19

Family

ID=46298646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280027766.8A Pending CN103596956A (zh) 2011-06-07 2012-05-24 吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途

Country Status (11)

Country Link
US (1) US8829010B2 (enExample)
EP (1) EP2718295A1 (enExample)
JP (1) JP2014516074A (enExample)
KR (1) KR101626681B1 (enExample)
CN (1) CN103596956A (enExample)
AU (1) AU2012265970A1 (enExample)
CA (1) CA2836851C (enExample)
IL (1) IL229606A0 (enExample)
MX (1) MX2013014470A (enExample)
SG (1) SG195085A1 (enExample)
WO (1) WO2012168817A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778331A (zh) * 2019-11-09 2021-05-11 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2021160131A1 (zh) * 2020-02-10 2021-08-19 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2014126954A1 (en) * 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Regioselective synthesis of substituted pyrimidines
CN104098574A (zh) * 2013-04-12 2014-10-15 苏州科捷生物医药有限公司 氮杂环丁烷取代嘧啶类化合物及其用途
WO2015026646A1 (en) * 2013-08-20 2015-02-26 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
MA50375A (fr) 2014-04-23 2021-05-26 Dart Neuroscience Cayman Ltd Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
AU2015357496B2 (en) * 2014-12-06 2019-09-19 Intra-Cellular Therapies, Inc. Organic compounds
KR102562576B1 (ko) 2014-12-06 2023-08-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2018091687A1 (en) 2016-11-18 2018-05-24 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN111447930A (zh) 2017-11-23 2020-07-24 奥斯陆大学医院公司 心动过速的治疗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072615A2 (en) * 2005-01-05 2006-07-13 Nycomed Gmbh Triazolophthalazines as pde2-inhibitors
CN102020645A (zh) * 2010-09-30 2011-04-20 中山大学 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
CN102491969B (zh) 2005-01-07 2015-08-19 辉瑞产品公司 杂芳族喹啉化合物及其作为pde10抑制剂的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072615A2 (en) * 2005-01-05 2006-07-13 Nycomed Gmbh Triazolophthalazines as pde2-inhibitors
CN102020645A (zh) * 2010-09-30 2011-04-20 中山大学 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778331A (zh) * 2019-11-09 2021-05-11 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN112778331B (zh) * 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2021160131A1 (zh) * 2020-02-10 2021-08-19 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Also Published As

Publication number Publication date
CA2836851C (en) 2016-06-21
MX2013014470A (es) 2014-03-21
EP2718295A1 (en) 2014-04-16
US20140080806A1 (en) 2014-03-20
CA2836851A1 (en) 2012-12-13
KR101626681B1 (ko) 2016-06-01
US8829010B2 (en) 2014-09-09
AU2012265970A1 (en) 2013-11-28
JP2014516074A (ja) 2014-07-07
WO2012168817A1 (en) 2012-12-13
IL229606A0 (en) 2014-01-30
KR20140019466A (ko) 2014-02-14
SG195085A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
CN103596956A (zh) 吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途
US9200000B2 (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
KR100896380B1 (ko) 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도
US12404261B2 (en) Compounds and compositions for treating conditions associated with cGAS
AU2012221828A1 (en) Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders
US11345681B1 (en) Inhibitors of fibroblast growth factor receptor kinases
TW201402564A (zh) 三唑化合物
HK1193814A (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
HK40085563A (en) Inhibitors of fibroblast growth factor receptor kinases
HK1188990A (en) IMIDAZO[5, 1-ƒ][1,2-4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
HK1167263B (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors
HK1113926A (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193814

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140219

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1193814

Country of ref document: HK